Chemical Polysialylation of Recombinant Human Proteins

  • Ivan V. Smirnov
  • Ivan I. Vorobiev
  • Alexey A. Belogurov
  • Dmitry D. Genkin
  • Sergey M. Deyev
  • Alexander G. Gabibov
Part of the Methods in Molecular Biology book series (MIMB, volume 1321)


Design of drug with prolonged therapeutic action is one of the rapid developing fields of modern medical science and required implementation of different methods of protein chemistry and molecular biology. There are several therapeutic proteins needing increasing of their stability, pharmacokinetic, and pharmacodynamics parameters. To make long-live DNA-encoded drug PEGylation was proposed. Alternatively polysialic (colominic) acid, extracted from the cell wall of E. coli, fractionated to the desired size by anion-exchange chromatography and chemically activated to the amine-reactive aldehyde form, may be chemically attached to the polypeptide chain. Conjugates of proteins and polysialic acid generally resemble properties of protein-PEG conjugates, but possess significant negative net charge and are thought to be fully degradable after endocytosis due to the presence of intracellular enzymes, hydrolyzing the polysialic acid. Complete biodegradation of the polysialic acid moiety makes this kind of conjugates preferable for creation of drugs, intended for chronic use. Here, we describe two different protocols of chemical polysialylation. First protocol was employed for the CHO-derived human butyrylcholinesterase with optimized for recovery of specific enzyme activity. Polysialic acid moieties are attached at various lysine residues. Another protocol was developed for high-yield conjugation of human insulin; major conjugation point is the N-terminal residue of the insulin’s light chain. These methods may allow to produce polysialylated conjugates of various proteins or polypeptides with reasonable yield and without significant loss of functional activity.

Key words

Chemical polysialylation Butyrylcholinesterase Insulin Polysialic acid Chemical conjugation Bioscavenger Long-acting therapeutic proteins 



The reported study was performed in the framework of the Russian Scientific Foundation Project no. 14-24-00106 (development, conjugation and purification of modified proteins) for IV, AB, DG, SD, AG and partially supported by Program of Presidium of the Russian Academy of Science “Molecular Cell Biology” (evaluation of BChE activity) for IS.


  1. 1.
    Geyer BC, Latha Kannan L, Garnaud PE et al (2010) Plant-derived human butyrylcholinesterase, but not an organophosphorous-compound hydrolyzing variant thereof, protects rodents against nerve agents. Proc Natl Acad Sci U S A 107:20251–20256PubMedCentralPubMedCrossRefGoogle Scholar
  2. 2.
    Rosenberg YJ, Saxena A, Sun W et al (2010) Demonstration of in vivo stability and lack of immunogenicity of a polyethyleneglycol-conjugated recombinant CHO-derived butyrylcholinesterase bioscavenger using a homologous macaque model. Chem Biol Interact 187:279–286PubMedCrossRefGoogle Scholar
  3. 3.
    Chilukuri N, Sun W, Naik RS et al (2008) Effect of polyethylene glycol modification on the circulatory stability and immunogenicity of recombinant human butyrylcholinesterase. Chem Biol Interact 175:255–260PubMedCrossRefGoogle Scholar
  4. 4.
    Levy Y, Hershfield MS, Fernandez-Mejia C et al (1988) Adenosine deaminase deficiency with late onset or recurrent infections: response to treatment with poly(ethyl-applicaene glycol) modified adenosine deaminase. J Pediatr 113:312–7PubMedCrossRefGoogle Scholar
  5. 5.
    Graham LM (2003) Pegasparaginase: a review of clinical studies. Adv Drug Deliv Rev 10:1293–302CrossRefGoogle Scholar
  6. 6.
    Hak LJ, Relling MV, Cheng C et al (2004) Asparaginase pharmacodynamics differ by formulation among children with newly diagnosed acute lymphoblastic leukemia. Leukemia 18:1072–7PubMedCrossRefGoogle Scholar
  7. 7.
    Wang YS, Youngster S, Grace M et al (2002) Structural and biological characterization of pegylated recombinant interferon alpha-2b and its therapeutic implications. Adv Drug Deliv Rev 54:547–70PubMedCrossRefGoogle Scholar
  8. 8.
    Monkarsh SP, Ma Y, Aglione A et al (1997) Positional isomers of mono-pegylated interferon α-2a: isolation, characterization, and biological activity. Anal Biochem 247:434–40PubMedCrossRefGoogle Scholar
  9. 9.
    Roelfsema F, Biermasz NR, Pereira AM et al (2006) Nanomedicines in the treatment of acromegaly: focus on pegvisomant. Int J Nanomedicine 1:385–98PubMedCentralPubMedCrossRefGoogle Scholar
  10. 10.
    Pasut G, Veronese FM (2007) Polymer-drug conjugation, recent achievements and general strategies. Prog Polym Sci 32:933–61CrossRefGoogle Scholar
  11. 11.
    Blick S, Curran M (2007) Certolizumab pegol. Biodrugs 21:196–201CrossRefGoogle Scholar
  12. 12.
    Vorobiev I, Matskevich V, Kovnir S et al (2013) Chemical polysialylation: Design of conjugated human oxyntomodulin with a prolonged anorexic effect in vivo. Biochimie 95:264–270PubMedCrossRefGoogle Scholar
  13. 13.
    Gregoriadis G, McCormack B, Wang Z et al (1993) Polysialic acids: potential in drug delivery. FEBS Lett 315:271–276PubMedCrossRefGoogle Scholar
  14. 14.
    Gregoriadis G, Jain S (2010) Polysialylation: next generation to PEGylation. Control Rel Soc Newsl 2:21–23Google Scholar
  15. 15.
    Gregoriadis G, Jain S, Papaioannou I et al (2005) Improving the therapeutic efficacy of peptides and proteins: a role for polysialic acid. Int J Pharma 300:125–130CrossRefGoogle Scholar
  16. 16.
    Jain S, Hreczuk-Hirst DH, Laing P et al (2004) Polysialylation: the natural way to improve the stability and pharmacokinetics of protein and peptide drugs. Drug Deliv Syst Sci 4:3–9Google Scholar
  17. 17.
    Ilyushin D, Smirnov IV, Belogurov AA Jr et al (2013) Chemical polysialylation of human recombinant butyrylcholinesterase delivers a long-acting bioscavenger for nerve agents in vivo. Proc Natl Acad Sci U S A 110:1243–8PubMedCentralPubMedCrossRefGoogle Scholar
  18. 18.
    Ellman GL, Courtney KD, Andres V et al (1961) A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 7:88–95PubMedCrossRefGoogle Scholar
  19. 19.
    Svennerholm L (1957) Quantitative estimation of sialic acids. A colorimetric resorcinol-hydrochloric acid method. Biochim Biophys Acta 24:604–611PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  • Ivan V. Smirnov
    • 1
    • 2
  • Ivan I. Vorobiev
    • 3
  • Alexey A. Belogurov
    • 1
    • 2
    • 4
  • Dmitry D. Genkin
    • 5
  • Sergey M. Deyev
    • 1
    • 6
  • Alexander G. Gabibov
    • 1
    • 2
    • 4
    • 7
  1. 1.Shemyakin–Ovchinnikov Institute of Bioorganic Chemistry of the RASMoscowRussia
  2. 2.Kazan Federal UniversityKazanRussia
  3. 3.Centre “Bioengineering” of the RASMoscowRussia
  4. 4.Institute of Gene Biology of the RASMoscowRussia
  5. 5.R&D Laboratories and Business Development OfficeXenetic Biosciences plcLondonUK
  6. 6.Lobachevsky State University of Nizhny NovgorodNizhny NovgorodRussia
  7. 7.Chemistry DepartmentMoscow State UniversityMoscowRussia

Personalised recommendations